You searched for "implant"
Patients blinded by stem cells! How safe are they really?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...Stent inject® W shelf life extended from 12 months to three years
Glaukos is delighted to announce that the expiry date for their innovative iStent inject® W device has been increased from 12 months to three years.A missed intraocular telescope – an opportunity to re-focus the evidence
Intraocular telescopes allow magnification of the image so that it would be projected into a larger area of the macula, this makes the central defect caused by dry age-related macular degeneration (AMD) smaller. The most common approach is a Galilean...Clinical and management strategies in glaucoma practice: perspectives from international glaucoma specialists
Management options and outcomes in glaucoma practice were reviewed at the 7th Moorfields International Glaucoma Symposium, held in London on 24 January 2015. This article summarises perspectives from international glaucoma specialists on debated issues in topical therapy, glaucoma surgery, diagnostic...Intraocular lens technology to deliver enhanced optical performance after cataract refractive surgery
Modern cataract surgery aims to provide patients with the best possible visual outcome with the least dependence on spectacles and minimal or no complications and to treat both cataract and refractive errors with a single procedure. Phacoemulsification is the standard...Do steroids prevent progression to proliferative diabetic retinopathy (PDR)?
There is continuing debate on the merits of pan-retinal photocoagulation (PRP) for severe pre-proliferative and proliferative DR versus the newer therapies that inhibit vascular endothelial growth factor (VEGF). This has been hotly debated [1] following the publication of findings from...What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace
Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...Cutting-edge practice in glaucoma care: what, how and why?
More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...A closer look at the new wave of glaucoma surgery – radical or old school?
Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...Newer generation IOL platforms designed for high-quality visual performance after cataract surgery
Expanding intraocular lens (IOL) capabilities provide broadening options, ranging from next-generation monofocal IOLs for basic cataract surgery, to specialised premium IOLs for lens-based presbyopia correction and astigmatism correction at the time of cataract surgery. Rod McNeil considers several newer alternative...Birdshot retinochoroiditis
Birdshot retinochoroiditis (BRC) is a chronic, sight-threatening uveitis, most commonly affecting caucasian individuals in their fourth to sixth decades [1]. The disease is associated with HLA-29 and is characterised by progressive inflammation at the level of retina and choroid, with...
